Cipla

By Courier

May 18, 2018

Shri. Umeshchandra Barkur A-15, Neeta Apartments Chaphekar Bandhu Marg Mulund East, Mumbai-400 081

Re: Your letter dated May 9, 2018 ("the Letter")

Dear Sir,

We are in receipt of the Letter addressed to Cipla Limited ("the Company.")

At the outset, we once again express our deepest condolences on the sad demise of your wife Smt. Kamini Barkur and share your grief.

We find the contents of the Letter absolutely contradictory to the facts on record and the assertions already made by you and consequently fully deny each and every allegation, contention and claim made in the Letter, as if they were here specifically set out and traversed; as being utterly misconceived, devoid of any merit and *mala fide*. Nothing in the Letter is to be deemed admitted unless specifically so stated in this reply. Without prejudice to the generality of the foregoing denial, we wish to state as under.

We do acknowledge the assertion you made in your email addressed to the Company on April 18, 2017 reading "I am not accusing Cipla in any manner." This opinion clearly underscores the status of the matter, correlative with the reported entry by the treating doctor in the in-patient records, a narration said to read "post Zobone arthralgia." We request your attention to the fact that Zobone is not a Company drug product. Clearly, after the exhaustive correspondence in this matter, the fresh contentions made by you in your Letter are merely an afterthought expressed with an obvious ulterior motive of improperly coercing the Company.

We are surprised you have elected to write the Letter more than four years following the sad demise of your wife, irrespective of there having been no further development in this regard. We are shocked to read the absolutely false and frivolous allegations you make against the Company and its senior management and board members, who are not in any manner involved in the day-to-day management of the Company, particularly if at all, on the issues alleged in the Letter. The Company has adequately addressed and responded to the several complaints and proceedings initiated by you with the respective authorities.

Cipla Ltd. Regd. Office Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai- 400 013

Phone +91 22 24826000 Fax +91 22 24826120 E-mail contactus@cipla.com Website www.cipla.com

Corporate Identity Number L24239MH1935PLC002380

150

Cipla

As you are aware, the Company is a well-known pharmaceutical corporation of repute in India and across the world, manufacturing and supplying quality products at affordable prices globally. It has at every instance offered assistance to you, its representatives having communicated with you personally and addressed all your concerns.

Without prejudice to the foregoing assertions, it is necessary to emphasise that the Company's drug IV Rokfos was granted marketing authorisation in India on July 20, 2010 and manufacturing license, on satisfactory completion of all necessary approval procedures. It is absolutely denied that the Company had sponsored administration of IV Rokfos in clinical trial or at all.

In view of the unfortunate demise of your wife and out of respect of your sentiments we have at all times dealt with you with the utmost courtesy and extended all assistance in respect of your queries and concerns. It appears that your intent with oblique motive is to falsely implicate the Company as being complicit in your wife's tragic death. This is both unfounded and unfortunate. In view of the above we call upon you to forthwith withdraw your letter and refrain from making such false and fake allegations against the Company and its senior management. Despite the above, should you nevertheless continue to make such allegations, the Company shall be constrained to and left with no alternative but to initiate legal proceedings against you as it may be advised, including for defamation, at your sole risk as to the consequences.

Your faithfully, For Cipla Limited

Authorised Representative